Type 2 Diabetes and Obesity

Clario helps sponsors manage the growing complexity of type 2 diabetes and obesity trials by bringing imaging, patient-reported outcomes, and cardiac safety together into a single, coordinated approach.

Rather than managing separate vendors and workflows, sponsors can align imaging, eCOA, cardiac safety monitoring within one provider. This makes it easier to collect consistent data, reduce operational burden, and keep studies running smoothly from early phase through submission.

Type 2 diabetes and obesity trials now require a broader view of treatment impact beyond weight loss or glycemic control. Sponsors need to understand changes in fat distribution, muscle mass, cardiovascular health, symptoms, and patient experience.

Clario supports this by integrating imaging, eCOA, and cardiac assessments into a unified strategy. This allows sponsors to capture both clinical outcomes and patient perspective while maintaining consistency across endpoints and reducing complexity for sites.

Clario supports a comprehensive set of endpoints designed to reflect real-world treatment effects.

Imaging is used to assess visceral and subcutaneous fat, liver fat, cardiac structure and function, and brain changes. eCOA captures patient-reported outcomes such as symptoms, quality of life, and treatment experience. Cardiac safety solutions monitor ECG, arrhythmias, and cardiovascular risk.

Together, these endpoints provide a more complete understanding of efficacy and safety across the study population.

Safety is a central concern in diabetes and obesity trials, especially given the elevated cardiovascular risk in these populations. 

Clario supports safety through integrated cardiac monitoring, event adjudication, and patient-reported data collection. This includes ECG monitoring, adjudication of major adverse cardiovascular events, and eCOA tools to capture symptoms such as hypoglycemia or treatment-related side effects. 

By combining these data streams, sponsors gain a clearer and more consistent view of patient safety throughout the trial. 

Clario helps reduce the operational complexity that often slows down diabetes and obesity trials by aligning imaging, eCOA, and cardiac workflows within a single ecosystem. 

Standardized processes, centralized data collection, and integrated technologies reduce duplication and minimize manual effort. Sites benefit from fewer systems to manage, and sponsors gain more consistent data across endpoints. 

This leads to fewer delays, lower site burden, and a more streamlined experience for both sites and patients. 

GLP-1 and dual agonist therapies are shifting endpoint strategy toward a more comprehensive view of metabolic health. In addition to weight loss and glycemic control, sponsors are increasingly focused on body composition, cardiovascular outcomes, and patient experience. 

Clario supports this shift by combining imaging, eCOA, and cardiac safety into a unified endpoint strategy. Imaging helps quantify changes in fat distribution and organ health, cardiac monitoring supports assessment of cardiovascular risk, and eCOA captures how patients feel and function during treatment. 

This integrated approach helps sponsors demonstrate the full value of these therapies while generating the depth of data needed for regulatory and clinical decision making.